Clinical trials: High-Risk Prostate Cancer, open to volunteers
Prostate Cancer, Recurrent Prostate Cancer
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
This study will enroll 60 patients previously enrolled to MCC#18523, "A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men with Prostate Cancer…
- Trial name
- NCT03495427
- Testing
- F-DCFPyL Injection, PSMA PET
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response.
- Trial name
- GUNS (NCT04812366)
- Testing
- Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab
- Where
- 9 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- University of British Columbia
Prostate Cancer
Active Surveillance Plus (AS+): High-intensity Focused Ultrasound (HIFU) in Patients With Localized Prostate Cancer
PSA (Prostate-specific antigen) testing has significantly increased the number of men diagnosed with prostate cancer (PCa) and especially patients with low and intermediate risk disease.
- Trial name
- NCT04549688
- Testing
- high-intensity focused ultrasound, HIFU
- Where
- Norway
- Volunteers
- 250 people
- Sponsor
- The Hospital of Vestfold
Prostate Carcinoma, Stage I Prostate Cancer AJCC v8
CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
This clinical trial studies the safety of a computed tomography (CT) scan, with or without a magnetic resonance imaging (MRI) scan, in planning for high-dose-rate (HDR) prostate brachytherapy treatment in patients with prostate…
- Conditions
- Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT07859722
- Testing
- Magnetic Resonance Imaging, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Emory University
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Prostate Cancers, Breast Cancer
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings.
- Conditions
- Prostate Cancers, Breast Cancer, Head and Neck Cancer, Cancer
- Trial name
- PETRiS (NCT06970275)
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 850 people
- Sponsor
- XEOS Medical
Prostate Cancer
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
The purpose of this study is to determine if treatment with Darolutamide plus androgen deprivation therapy (ADT) before radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized…
- Trial name
- NCT06575257
- Testing
- Darolutamide, Goserelin 3.6 mg
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xijing Hospital
Hormone-refractory Prostate Cancer
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
There are many treatment options for men with various stages of prostate cancer. Some treatments work well for a while but can cause medical problems in some men. Also, the cancer may come back after treatment.
- Trial name
- NCT05997615
- Testing
- VIR-5500, Androgen receptor signaling inhibitor (ARSI), Docetaxel
- Where
- 26 sites in United States, Australia and 2 more
- Volunteers
- 347 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostatic Neoplasms
Men at High Genetic Risk for Prostate Cancer
Background: Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated…
- Trial name
- NCT03805919
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Radical Prostatectomy Without Prior Biopsy
This pilot comparative study will evaluate a one-stage diagnostic and surgical strategy for patients with a high probability of clinically significant prostate cancer who have not undergone a separate preoperative prostate…
- Trial name
- NCT07819760
- Testing
- Transperineal Fusion-Targeted Prostate Biopsy With Intraoperative Frozen Section Examination, Robot-Assisted Radical Prostatectomy With Pelvic Lymph Node Dissection, Standard Transperineal Fusion Prostate Biopsy
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Botkin Hospital
Prostate Cancer, Prostatic Neoplasms
Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial
The purpose of this study is to determine whether a 12-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among men with prostate cancer at high-risk of progression undergoing…
- Trial name
- NCT05918263
- Testing
- High-Intensity Interval Training Exercise Program
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostatic Neoplasm of Uncertain Behavior
Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer
Study Goal: The purpose of this clinical trial is to determine if combining high-frequency micro-ultrasound with multiparametric MRI biopsy and a systematic biopsy can better detect clinically significant prostate cancer compared…
- Trial name
- Biopsy29 (NCT06579911)
- Testing
- High-frequency micro-ultrasound target biopsy, conventional Multiparametric MRT target biopsy
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Salzburger Landeskliniken
Prostate Cancer
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal.
- Trial name
- NCT04700332
- Testing
- DCFPyL PET/CT
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Prostate Cancer
Focal Therapy for Localized Prostate Cancer
This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.
- Trial name
- NCT06270043
- Testing
- Focal Therapy
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Prostate Adenocarcinoma, Localized Prostate Carcinoma
Two-fraction HDR Monotherapy for Localized Prostate Cancer
This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart.
- Trial name
- NCT05665738
- Testing
- High Dose Rate Monotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
High Risk Prostate Carcinoma
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H)
Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients who underwent low-fractionation curative radiation therapy and hormone therapy
- Trial name
- DESAR-H (NCT06461793)
- Testing
- Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Localized Prostate Carcinoma
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy.
- Trial name
- BrachyTRACKS (NCT06200974)
- Testing
- High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
High Risk Prostate Carcinoma, Prostate Cancer
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
PEACE 7 is an international, multicenter, randomized, open-label phase III study that aims at evaluating the efficacy and safety of darolutamide and of stereotactic dose escalated prostate radiotherapy in patients with localised…
- Trial name
- PEACE 7 (NCT06625970)
- Testing
- Darolutamide, Stereotactic Body RadioTherapy (SBRT), ADT (Standard of Care)
- Where
- 6 sites in France, Martinique
- Volunteers
- 700 people
- Sponsor
- UNICANCER